Biopharma intelligence
Southeast Asia’s rising share of global trial volume
Why sponsors are diversifying geographies, and where the Philippines fits in the regional shift.
Sponsors have been moving trial volume out of saturated US/EU site networks and into Southeast Asia for several years now. Market-share figures for that shift are pending a cited source — what follows is the structural reasoning behind it, not a market-size claim.
Why sponsors are diversifying geographies
- Cost pressure on trial budgets, especially for larger Phase II/III programs.
- Site saturation in traditional US/EU academic centers, where the same patient pool is recruited against by multiple concurrent protocols.
- Regulatory pathways in the region maturing to a point sponsors are comfortable relying on them.
Where the Philippines fits in that shift
The three articles linked from this one — on cost, enrollment speed, and regulatory timeline — are the specific case for the Philippines within that broader regional shift, not a claim that it is the only option in Southeast Asia. Each geography in the region has a different mix of cost, population, and regulatory maturity, and the right fit depends on the protocol.
What this means for a sponsor deciding now
Treat "Southeast Asia" as a category, not a single decision — the operational realities of running a trial in the Philippines, Vietnam, or Indonesia differ enough that a geography decision should be made site-by-site, not region-by-region.